[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinopathy":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,90,135,163,184],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":45,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100286660","stem-cell-ophthalmology-treatment-study-ii-100286660",false,"NCT03011541","Stem Cell Ophthalmology Treatment Study II","Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II","SCOTS2","Inclusion Criteria:\n\n* Have objective, documented damage to the retina or optic nerve unlikely to improve OR\n* Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20\u002F30 best corrected central visual acuity in one or both eyes AND\u002FOR an abnormal visual field in one or both eyes.\n* Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.\n* If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).\n* Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n* Be over the age of 18\n* Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.\n* Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n* Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.\n* Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.\n* Patients who are not capable of providing informed consent.\n* Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Retinal Disease","Age-Related Macular Degeneration","Retinitis Pigmentosa","Stargardt Disease","Optic Neuropathy","Nonarteritic Ischemic Optic Neuropathy","Optic Atrophy","Optic Nerve Disease","Glaucoma","Leber Hereditary Optic Neuropathy","Blindness","Vision Loss Night","Vision Loss Partial","Vision, Low","Retinopathy","Maculopathy","Macular Degeneration","Retina Atrophy",[46,47,48,49,50,51,52,53,54,27,43,55,56,57,58,59,60,61,62,63,29,30,64,65,66,42,34,33,31,67,68,69,70,71,72,73,74,75,36,37,76,44],"Stem Cells","Bone Marrow Derived Stem Cells","BMSC","Mesenchymal Stem Cells","MSC","Eye Disease","Ophthalmology","Ophthalmic Disease","Retina","Age Related Macular Degeneration","Myopic Macular Degeneration","Geographic Atrophy","Dry Macular Degeneration","Wet Macular Degeneration","Retinal Atrophy","Retinal Dystrophy","Hereditary Retinal Dystrophy","Malattia Leventinese","Cone Dystrophy","Rod-Cone Dystrophy","Cone-Rod Dystrophy","Ischemic Optic Neuropathy","Optic Nerve Damage","Optic Nerve Compression","Compressive Optic Neuropathy","Devics Syndrome","Ushers Syndrome","Neuromyelitis Optica","Dominant Optic Atrophy","Kjers Optic Atrophy","Vision Loss","RECRUITING","2026-06-24",{"date":80,"type":81},"2026-06-29","ACTUAL",{"date":83,"type":81},"2016-01",{"date":85,"type":21},"2028-07-31",{"name":87,"class":88},"MD Stem Cells","INDUSTRY",4,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":101,"conditions":102,"keywords":111,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":134},"100580429","studying-the-presence-of-cfrd-complications-with-thoughtful-recruitment-spectrum-100580429","NCT06837181","Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)","SPeCTRuM","Inclusion Criteria:\n\n* Written informed consent (and assent when applicable) obtained from participant or participant's legally authorized representative\n* For Adults: Must be able to consent on one own's behalf (i.e., cannot lack cognitive capacity to consent due to the required patient-reported outcomes)\n* Be willing and able to adhere to the study protocol requirements\n* Age ≥ 12 years at time of enrollment\n* CF diagnosis based on two CF causing mutations and\u002For positive sweat test according to CFF diagnostic criteria\n* CFRD diagnosis ≥ 5 years at time of enrollment\n\nExclusion Criteria:\n\n* History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk to the subject\n* History of transplant\n* Pregnancy reported by participant at time of consent or at any point during active study participation\n\nPulse Wave Velocity Exclusion Criteria:\n\n* Erratic, accelerated or mechanically controlled irregular heart rhythms including arrhythmias\n* Carotid or aortic valve stenosis\n* Peripheral artery disease or leg artery disease\n* Generalized constriction or localized spasm of muscular conduit arteries such as seen immediately after hypothermic cardiopulmonary bypass surgery or accompanying Raynaud's phenomena or intense cold.\n* Possible exclusions based on investigator medical provider assessment (additional precautions may be followed to allow inclusion):\n\n  * Pressure reading should not be conducted on a limb where there is intravenous access, arterio-venous shunt, or where circulation is compromised.\n  * Pressure reading should not be conducted on the side of the body that a mastectomy was done.","12 Years",{"count":99,"type":21},200,"OBSERVATIONAL","This multicenter cross-sectional study will include a diverse population of adolescents and adults with CF.\n\nThe overall Aim is to describe prevalence of diabetes microvascular complications and macrovascular surrogates in people with established CFRD.",[103,104,105,41,106,107,108,109,110],"Cystic Fibrosis (CF)","Cystic Fibrosis-related Diabetes","Diabetes","Neuropathy","Nephropathy","Blood Pressure","Cardiovascular Risk","Microvascular",[112,113,114,115,116,117,118,105,119,120,121,122,123],"Cystic Fibrosis","CFRD","Cystic Fibrosis-Related Diabetes","Observational","Physical Activity Tracker","Continuous glucose monitoring","CGM","blood pressure","cardiovascular risk","microvascular","diabetes complications","social determinants of health","2026-02-09",{"date":126,"type":81},"2026-02-10",{"date":128,"type":81},"2025-09-18",{"date":130,"type":21},"2028-11-30",{"name":132,"class":133},"Jaeb Center for Health Research","OTHER",18,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100363123","early-phase-1-feasibility-and-safety-of-mb-102-in-ocular-angiography-as-compared-to-fluorescein-sodium-100363123","NCT04008121","Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium","A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium","Inclusion Criteria:\n\n* Age \\> 18 years - male or female\n\n  1. Eligible female non-pregnant participants who are either not of child-bearing potential or willing to utilize adequate contraception during the trial\n  2. Males must be willing to practice abstinence or utilize adequate contraception from MB-102 dosing day to at least 7 days post dose\n* Participants willing to comply with study requirements\n* Participants who have signed an informed consent form\n\nAt least 5 participants will have a current history of retinal or choroidal vascular diseases.\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating or planning to become pregnant during the study, or women who are of childbearing potential unwilling to utilize adequate contraception\n* Participation in another interventional trial within 30 days of treatment or concurrently enrolled in any other medical research study which could impact the results of the study\n* History of drug or alcohol abuse within the past year\n* History of severe allergic hypersensitivity reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 and fluorescein sodium or other related products (intolerance to a drug is not considered a drug allergy).\n* Prior history of seizures\n* Current visually significant cataracts or other ophthalmic conditions that would limit appropriate collection of fundus photographs\n* Site personnel immediately associated with the study or their immediate family members\n* Unable to tolerate ophthalmologic imaging\n* Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial (e.g. unstable medical condition including cardiovascular disease, or other conditions considered clinically significant or unstable by the Principal Investigator)\n* Prior enrollment and dosing in this study",true,{"count":144,"type":21},10,[146],"EARLY_PHASE1","The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.",[41,149,150,43],"Retinal Vein Occlusion","Diabetic Retinopathy",[152],"Fluorescein angiography","2026-02-02",{"date":155,"type":81},"2026-02-04",{"date":157,"type":81},"2025-11-06",{"date":159,"type":21},"2026-12",{"name":161,"class":88},"MediBeacon",1,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":162},"100425433","study-of-the-involvement-of-fatty-acids-in-retinopathy-of-prematurity-relationship-between-retinopathy-of-prematurity-and-the-rate-of-expression-of-transplacental-fatty-acid-receptors-100425433","NCT04819893","Study of the Involvement of Fatty Acids in Retinopathy of Prematurity: Relationship Between Retinopathy of Prematurity and the Rate of Expression of Transplacental Fatty Acid Receptors.","OMEGAROP 2","Inclusion Criteria:\n\n1. Mothers giving birth to premature babies less than 29 weeks of amenorrhea (WA), after obtaining their non-opposition.\n2. Mothers giving birth at term between 39 and 41WA+6 days, after obtaining their non-opposition.\n3. ≥18 years\n4. Mothers not under legal protection\n\nExclusion Criteria:\n\n1. Mothers giving birth between 29WA and 38WA+6 days\n2. Mothers in critical condition.\n3. Person not affiliated to national health insurance\n4. For full-term mothers: patient presenting or having presented a health condition that affected a previous pregnancy (vascular such as pregnant hypertension, preeclampsia; gestational diabetes; intrauterine growth retardation, maternal infection during pregnancy such as toxoplasmosis, cytomegalovirus, rubella, measles, chickenpox).",{"count":171,"type":21},135,"The development of the retinal vascular network is completed during the third trimester of pregnancy and and the first 15 days of life of the newborn. This late maturation can be problematic in cases of preterm births and result in immature retinal vascularization, known as retinopathy of prematurity (ROP). Among the various factors influencing retinal vascular development, the tissue content of omega-3 polyunsaturated fatty acids (PUFAs) appears to be a crucial element. In a previous project, OMEGA-ROP, we showed a difference in the blood bioavailability of omega-3 PUFAs in infants born at less than 28 weeks of amenorrhea who develop ROP compared to healthy newborns with no retinopathy. This study also showed that mothers experienced variations in the blood levels of omega-3 PUFAs that were contrary to the types of variations observed in their children. This suggests a sequestration of omega-3 PUFAs in the mothers of children who will develop ROP. This new project aims to better understand the underlying molecular mechanisms by studying the expression levels of placental fatty acid receptors in relation to the development of ROP in newborns.",[174,41],"Prematurity","2025-09-17",{"date":177,"type":81},"2025-09-22",{"date":179,"type":81},"2021-04-20",{"date":181,"type":21},"2027-02",{"name":183,"class":133},"Centre Hospitalier Universitaire Dijon",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":142,"sex":17,"minAge":192,"maxAge":4,"enrollmentInfo":193,"targetDuration":195,"studyType":100,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":162},"100327409","cognitive-impairment-retinopathy-and-cerebrovascular-lesions-in-the-elderly-100327409","NCT03542734","Cognitive Impairment, Retinopathy, and Cerebrovascular Lesions in the Elderly","The Associations of Retinal Microvascular Signs and Brain Imaging Markers With Cognitive Impairment in Patients With Small Vessel Disease","CIRCLE","Inclusion Criteria:\n\n* Adult (≥40y; no upper limit)\n* Free of known dementia or stroke (both cerebral infarction and hemorrhage)\n\nExclusion Criteria:\n\n* Any MRI contraindications\n* Serious head injury (resulting to loss of consciousness) or received intracranial surgery\n* Suffering from cancer","40 Years",{"count":194,"type":21},1000,"5 Years","The CIRCLE study is a single-center prospective observational study that enrolled individuals with cerebral small vessel disease (SVD), while free of known dementia or stroke (both cerebral infarction and hemorrhage). The patients will receive neuropsychological testing, retinal digital images and multimodal magnetic resonance imaging (MRI). Blood samples will also be collected. Recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and brain atrophy will be evaluated on both baseline and follow-up brain MRIs. The investigators will explore the predictors of preogression of SVD and cognitive deficits.",[198,41,199],"Cerebral Small Vessel Diseases","Cognitive Dysfunction","2023-02-02",{"date":202,"type":81},"2023-02-06",{"date":204,"type":81},"2010-01-01",{"date":206,"type":21},"2031-06-30",{"name":208,"class":133},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]